Latest Patent Grants News

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.

EcoGraf Limited has been granted a second Australian patent for its HFfree® purification technology, reinforcing its position in the sustainable battery materials market. This patent extends protection for its innovative graphite purification process critical to lithium-ion battery anode production and recycling.

Synertec Corporation reports a 7.7% revenue increase in FY25 Q3, highlights robust Powerhouse technology performance during extreme weather, and secures a US patent for its LNG Custody Transfer System.

Quantum Graphite Limited has been granted Major Project Status by the Australian Government for its Quantum-Sunlands Eyre Peninsula Graphite Hub, marking a significant milestone in its graphite supply chain development. Concurrently, the company progresses a US$300 million financing application with the US EXIM Bank and secures an Australian patent for its joint venture’s thermal energy storage technology.

Sparc Technologies has progressed to Stage 2 of its Sparc Hydrogen joint venture with pilot plant commissioning slated for mid-2025, while also securing its first patent for photocatalytic water splitting technology in Morocco. Concurrently, its graphene-based additive ecosparc® demonstrates promising field trial results, underpinning commercial momentum.

Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

Nanoveu Limited reports strong momentum in its EyeFly3D technology with a significant purchase order and launches an AI-powered app, while advancing its strategic acquisition of semiconductor innovator EMASS.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.